Ravi Singh to Antineoplastic Agents
This is a "connection" page, showing publications Ravi Singh has written about Antineoplastic Agents.
Connection Strength
1.075
-
Fahrenholtz CD, Ding S, Bernish BW, Wright ML, Zheng Y, Yang M, Yao X, Donati GL, Gross MD, Bierbach U, Singh R. Design and cellular studies of a carbon nanotube-based delivery system for a hybrid platinum-acridine anticancer agent. J Inorg Biochem. 2016 12; 165:170-180.
Score: 0.379
-
Swanner J, Mims J, Carroll DL, Akman SA, Furdui CM, Torti SV, Singh RN. Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells. Int J Nanomedicine. 2015; 10:3937-53.
Score: 0.350
-
McCarthy B, Singh R, Levi-Polyachenko N. Oxaliplatin-resistant colorectal cancer models for nanoparticle hyperthermia. Int J Hyperthermia. 2021; 38(1):152-164.
Score: 0.129
-
Peak TC, Panigrahi GK, Praharaj PP, Su Y, Shi L, Chyr J, Rivera-Chávez J, Flores-Bocanegra L, Singh R, Vander Griend DJ, Oberlies NH, Kerr BA, Hemal A, Bitting RL, Deep G. Syntaxin 6-mediated exosome secretion regulates enzalutamide resistance in prostate cancer. Mol Carcinog. 2020 01; 59(1):62-72.
Score: 0.119
-
Zheng Y, Fahrenholtz CD, Hackett CL, Ding S, Day CS, Dhall R, Marrs GS, Gross MD, Singh R, Bierbach U. Large-Pore Functionalized Mesoporous Silica Nanoparticles as Drug Delivery Vector for a Highly Cytotoxic Hybrid Platinum-Acridine Anticancer Agent. Chemistry. 2017 Mar 08; 23(14):3386-3397.
Score: 0.098